Sound Shore Management Inc. CT Has $76.50 Million Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

Posted by Stanley Muller on Jun 4th, 2026

Sound Shore Management Inc. CT trimmed its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 5.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 850,757 shares of the medical equipment provider’s stock after selling 45,527 shares during the quarter. Zimmer Biomet comprises approximately 2.4% of Sound Shore Management Inc. CT’s holdings, making the stock its 28th largest position. Sound Shore Management Inc. CT’s holdings in Zimmer Biomet were worth $76,500,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Key Financial Inc lifted its stake in shares of Zimmer Biomet by 164.6% in the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 163 shares during the last quarter. Flagship Harbor Advisors LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter worth $32,000. Grove Bank & Trust lifted its stake in shares of Zimmer Biomet by 431.6% in the fourth quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 328 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of Zimmer Biomet in the second quarter worth $37,000. Finally, Basepoint Wealth LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter worth $38,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. BTIG Research restated a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. Wall Street Zen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. UBS Group restated a “sell” rating and issued a $89.00 price objective on shares of Zimmer Biomet in a research note on Wednesday, February 11th. Wells Fargo & Company dropped their target price on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 29th. Finally, Citigroup dropped their target price on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a research report on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and an average price target of $102.70.

Check Out Our Latest Report on Zimmer Biomet

Zimmer Biomet Trading Up 1.6%

Shares of ZBH stock opened at $85.11 on Thursday. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $108.29. The firm’s fifty day simple moving average is $87.68 and its 200 day simple moving average is $90.52. The firm has a market capitalization of $16.47 billion, a P/E ratio of 22.11, a price-to-earnings-growth ratio of 1.94 and a beta of 0.47. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last announced its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The business had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.07 billion. During the same quarter in the previous year, the firm posted $1.81 earnings per share. Zimmer Biomet’s revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Thursday, June 25th. Zimmer Biomet’s payout ratio is 24.94%.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the business’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the sale, the senior vice president owned 10,224 shares of the company’s stock, valued at $967,803.84. The trade was a 20.58% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares in the company, valued at $2,252,022.64. This trade represents a 15.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 1.28% of the company’s stock.

Zimmer Biomet Company Profile

(Free Report)

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.